Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (XOMAO) SEC filings page on Stock Titan is intended to organize regulatory documents related to XOMA Royalty’s preferred stock and broader capital structure. While no specific SEC filings are listed in the provided data, XOMA Royalty’s press releases describe a business model and transaction activity that are typically reflected in formal filings such as annual reports, quarterly reports, and registration statements.
XOMA Royalty characterizes itself as a biotechnology royalty aggregator that acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. When it acquires these future economic rights, the seller receives non-dilutive, non-recourse funding. The company also explains that its portfolio consists of milestone and royalty rights associated with baskets of drug products in development, and that its assets are milestone and royalty rights tied to individual drug products.
For a security like XOMAO, which represents depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock, SEC filings are the primary source for detailed terms of the preferred stock, including dividend provisions, ranking, and any redemption or liquidation preferences. In addition, XOMA Royalty’s acquisitions of companies such as HilleVax, LAVA Therapeutics, and Mural Oncology, along with royalty sharing transactions like the amended Takeda collaboration, are the types of material events that are generally described in current reports and periodic filings.
On Stock Titan, the XOMAO filings page can be used alongside XOMA Royalty’s public press releases to understand how the company reports its royalty and milestone portfolio, commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, and the impact of corporate transactions on its financial position. AI-powered summaries can help explain lengthy filings by highlighting sections that relate to preferred stock terms, royalty and milestone accounting, and the structure of acquisitions and royalty-sharing agreements.
Investors reviewing XOMAO may look to SEC documents for details on cumulative preferred dividend obligations, the relationship between the preferred stock and common equity, and disclosures about the risks and potential variability of royalty and milestone income. Combined with the company’s own explanatory notes on how it defines “portfolio” and “assets,” these filings provide a regulatory view of XOMA Royalty’s royalty aggregation strategy and the securities it has issued, including the Series B preferred stock represented by XOMAO.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.